Altimmune, Inc. — Director's Dealing 2023

Feb 1, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2023-01-30

Reporting Person: Roberts M Scot (Chief Scientific Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-01-30	Stock Options (option to buy)	$12.88	A	105000	Acquired	2033-01-30	Common Stock, par value $0.0001 (105000)	Direct
2023-01-30	Restricted Stock Units	$	A	37100	Acquired		Common Stock, par value $0.0001 (37100)	Direct

Footnotes

F1: Twenty-five percent of the shares underlying the option become vested and exercisable on January 30, 2024 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 30, 2024, subject to the reporting person's continued service through the applicable vesting date.

F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.

F3: The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.